ScienceDex / Researcher record
Meyers, Charles Daniel
- Tempero Bio, Inc. (no department on record)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
- Program Leader
- Early Career
NIH Funding · FY2022
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2022 | $2,060,520 | 1 | #3,451 |
| 2023 | $3,250,400 | 1 | #1,583 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2022 · selected1 record
- FY20231 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2022 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award records by amount
NIH award records listing Meyers, Charles Daniel as a PI. Multi-PI records show the full award amount for context.
- 1U01DA057118-01U01Contact PITMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder$2.1Maward amount
Award organization
Organizations that administered FY2022 awards listing Meyers, Charles Daniel as a PI.
FY2022 award administered by Tempero Bio, Inc. ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2022First NIH AwardTempero Bio, Inc.
- 2022$500K Cumulative Funding
- 2022$1M Cumulative Funding
- 2022$2M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #3451
- 2022Entered Top 25% NationallyRanked #3451
- 2023$5M Cumulative Funding
- 2023Entered Top 10% NationallyRanked #1583